We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

OPKO Health to Acquire PROLOR Biotech

News   Apr 30, 2013

 
OPKO Health to Acquire PROLOR Biotech
 
 
 

RELATED ARTICLES

Discontinuing Oral Immunotherapy for Peanut Allergy Reduces Its Protective Effects

News

A study has followed participants after oral immunotherapy (OIT) for peanut allergy have found that discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects.

READ MORE

Perfecting a Method To Predict the Potential of New Drugs

News

Researchers are perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

READ MORE

B Cells May Be More Important in Immunotherapy Than Previously Thought

News

Researchers have found evidence that B cells might play an important role in immunotherapy for melanoma. Currently, immunotherapy is primarily focused on T cells, but the results suggest that B cells could also provide an interesting research avenue.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE